Daymark Wealth Partners LLC Acquires 112 Shares of Novo Nordisk A/S (NYSE:NVO)

Daymark Wealth Partners LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,402 shares of the company’s stock after buying an additional 112 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $762,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $25,000. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Dixon Mitchell Investment Counsel Inc. bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Finally, Orion Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at $26,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Trading Up 0.5 %

Novo Nordisk A/S stock opened at $117.57 on Friday. The stock has a 50-day simple moving average of $129.84 and a 200 day simple moving average of $132.16. The stock has a market capitalization of $527.60 billion, a P/E ratio of 40.54, a PEG ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52 week low of $92.94 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. Analysts expect that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.